NCT07218367Not yet recruitingPhase 1
Phase I Trial of pH Resections of GBM at VA
Targeting Infiltrating Glioblastoma Via pH Sensitive Visualization of Tumor and pH Modulation Through Bicarbonate Transporter SLC4A4
Source: ClinicalTrials.gov · Last updated 13 Feb 2026
Brief summary (registry, in English)
Glioblastoma is an infiltrating tumor that is difficult to visualize in surgery and on standard images. A special pH (acid-base) related magnetic resonance imaging (MRI) has been developed to better see infiltrating tumor. In this safety study, the investigators will carry out increased levels of pH based resections of infiltrating tumor to assess the tolerability in VA populations.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 15 Oct 2025
- Start date
- 1 Jul 2026
- Primary completion date
- 1 Jul 2031
- Lead sponsor
- VA Office of Research and Development
- Diseases
- Glioblastoma
- NCT number
- NCT07218367
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 12
- From 1 Jul 2026 to the primary completion date, 1 Jul 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diagnostic uncertainty such as history of extracranial malignancy or autoimmune disease
- Medical conditions prohibiting anesthesia or surgery
Other
- Tumors involving eloquent brain areas as defined by MRI signal
- primary motor cortex, primary sensory cortex, sensorimotor fibers, primary language areas, arcuate fasciculus
Who the study is looking for
- Ability to provide written informed consent
- Karnofsky Performance Scale (KPS) of 70 or higher
- Suspected, newly diagnosed or recurrent IDH wild type WHO IV glioblastoma presenting as an intra-axial
- Expansile contrast-enhancing mass without evidence of metastatic disease
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| VA Greater Los Angeles Healthcare System, West Los Angeles, CA Coordinator of this site? Confirm its status | West Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.